These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31017249)

  • 1. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
    Nardin C; Pelletier F; Puzenat E; Aubin F
    Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
    Stauner CT; Drexler K; Berneburg M; Haferkamp S
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
    Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
    Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 6. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
    Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
    Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 11. Generalized morphea in the setting of pembrolizumab.
    Cheng MW; Hisaw LD; Bernet L
    Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
    Liu RC; Consuegra G; Chou S; Fernandez Peñas P
    Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
    Denny J; Chong H; Akhras V
    Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
    [No Abstract]   [Full Text] [Related]  

  • 14. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
    Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 17. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 19. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 20. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H; Bjursten S; Ny L; Levin M
    Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.